{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:16:51Z","timestamp":1792171011882,"version":"4.4.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>ATP-dependent P2X3 receptors play a crucial role in the sensitization of nerve fibers and pathological pain pathways. They are also involved in pathways triggering cough and may contribute to the pathophysiology of endometriosis and overactive bladder. However, despite the strong therapeutic rationale for targeting P2X3 receptors, preliminary antagonists have been hampered by off-target effects, including severe taste disturbances associated with blocking the P2X2\/3 receptor heterotrimer. Here we present a P2X3 receptor antagonist, eliapixant (BAY\u00a01817080), which is both highly potent and selective for P2X3 over other P2X subtypes in vitro, including P2X2\/3. We show that eliapixant reduces inflammatory pain in relevant animal models. We also provide the first in vivo experimental evidence that P2X3 antagonism reduces neurogenic inflammation, a phenomenon hypothesised to contribute to several diseases, including endometriosis. To test whether eliapixant could help treat endometriosis, we confirmed P2X3 expression on nerve fibers innervating human endometriotic lesions. We then demonstrate that eliapixant reduces vaginal hyperalgesia in an animal model of endometriosis-associated dyspareunia, even beyond treatment cessation. Our findings indicate that P2X3 antagonism could alleviate pain, including non-menstrual pelvic pain, and modify the underlying disease pathophysiology in women with endometriosis. Eliapixant is currently under clinical development for the treatment of disorders associated with hypersensitive nerve fibers.<\/jats:p>","DOI":"10.1038\/s41598-021-99177-0","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:10:54Z","timestamp":1633651854000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Eliapixant is a selective P2X3 receptor antagonist for the treatment of\u00a0disorders\u00a0associated with\u00a0hypersensitive\u00a0nerve fibers"],"prefix":"10.1038","volume":"11","author":[{"given":"Adam J.","family":"Davenport","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Neagoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Br\u00e4uer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rotgeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Laux-Biehlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Machet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikisha","family":"Carty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Gemkow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Zollner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver M.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,6]]},"reference":[{"key":"99177_CR1","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1111\/bph.13957","volume":"175","author":"LP Bernier","year":"2018","unstructured":"Bernier, L. P., Ase, A. R. & Seguela, P. P2X receptor channels in chronic pain pathways. Br. J. Pharmacol. 175, 2219\u20132230. https:\/\/doi.org\/10.1111\/bph.13957 (2018).","journal-title":"Br. J. Pharmacol."},{"key":"99177_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/bph.15299","volume":"178","author":"P Illes","year":"2021","unstructured":"Illes, P. et al. Update of P2X receptor properties and their pharmacology: IUPHAR Review 30. Br. J. Pharmacol. 178, 489\u2013514. https:\/\/doi.org\/10.1111\/bph.15299 (2021).","journal-title":"Br. J. Pharmacol."},{"key":"99177_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1113\/jphysiol.2005.088435","volume":"567","author":"DA Cockayne","year":"2005","unstructured":"Cockayne, D. A. et al. P2X2 knockout mice and P2X2\/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATP. J. Physiol. 567, 621\u2013639. https:\/\/doi.org\/10.1113\/jphysiol.2005.088435 (2005).","journal-title":"J. Physiol."},{"key":"99177_CR4","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/35039519","volume":"407","author":"DA Cockayne","year":"2000","unstructured":"Cockayne, D. A. et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature 407, 1011\u20131015. https:\/\/doi.org\/10.1038\/35039519 (2000).","journal-title":"Nature"},{"key":"99177_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/35039526","volume":"407","author":"V Souslova","year":"2000","unstructured":"Souslova, V. et al. Warm-coding deficits and aberrant inflammatory pain in mice lacking P2X3 receptors. Nature 407, 1015\u20131017. https:\/\/doi.org\/10.1038\/35039526 (2000).","journal-title":"Nature"},{"key":"99177_CR6","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3389\/fncel.2013.00236","volume":"7","author":"E Fabbretti","year":"2013","unstructured":"Fabbretti, E. ATP P2X3 receptors and neuronal sensitization. Front. Cell Neurosci. 7, 236. https:\/\/doi.org\/10.3389\/fncel.2013.00236 (2013).","journal-title":"Front. Cell Neurosci."},{"key":"99177_CR7","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.neuropharm.2012.11.011","volume":"67","author":"FC Prado","year":"2013","unstructured":"Prado, F. C. et al. Neuronal P2X3 receptor activation is essential to the hyperalgesia induced by prostaglandins and sympathomimetic amines released during inflammation. Neuropharmacology 67, 252\u2013258. https:\/\/doi.org\/10.1016\/j.neuropharm.2012.11.011 (2013).","journal-title":"Neuropharmacology"},{"issue":"Suppl 3","key":"99177_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/bcpt.12577","volume":"119","author":"KE Andersson","year":"2016","unstructured":"Andersson, K. E. Potential future pharmacological treatment of bladder dysfunction. Basic Clin. Pharmacol. Toxicol. 119(Suppl 3), 75\u201385. https:\/\/doi.org\/10.1111\/bcpt.12577 (2016).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"99177_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12894-015-0075-9","volume":"15","author":"K Svennersten","year":"2015","unstructured":"Svennersten, K., Hall\u00e9n-Grufman, K., de Verdier, P. J., Wiklund, N. P. & Poljakovic, M. Localization of P2X receptor subtypes 2, 3 and 7 in human urinary bladder. BMC Urol. 15, 81\u201381. https:\/\/doi.org\/10.1186\/s12894-015-0075-9 (2015).","journal-title":"BMC Urol."},{"key":"99177_CR10","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/S0140-6736(14)61255-1","volume":"385","author":"R Abdulqawi","year":"2015","unstructured":"Abdulqawi, R. et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough: A randomised, double-blind, placebo-controlled phase 2 study. Lancet 385, 1198\u20131205. https:\/\/doi.org\/10.1016\/S0140-6736(14)61255-1 (2015).","journal-title":"Lancet"},{"key":"99177_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pupt.2017.06.009","volume":"47","author":"SJ Bonvini","year":"2017","unstructured":"Bonvini, S. J. & Belvisi, M. G. Cough and airway disease: The role of ion channels. Pulm. Pharmacol. Ther. 47, 21\u201328. https:\/\/doi.org\/10.1016\/j.pupt.2017.06.009 (2017).","journal-title":"Pulm. Pharmacol. Ther."},{"key":"99177_CR12","doi-asserted-by":"publisher","first-page":"L858","DOI":"10.1152\/ajplung.90360.2008","volume":"295","author":"K Kwong","year":"2008","unstructured":"Kwong, K., Kollarik, M., Nassenstein, C., Ru, F. & Undem, B. J. P2X2 receptors differentiate placodal vs. neural crest C-fiber phenotypes innervating guinea pig lungs and esophagus. Am. J. Physiol. Lung Cell Mol. Physiol. 295, L858\u2013L865. https:\/\/doi.org\/10.1152\/ajplung.90360.2008 (2008).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"99177_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/14656566.2018.1462795","volume":"19","author":"NM Ryan","year":"2018","unstructured":"Ryan, N. M., Vertigan, A. E. & Birring, S. S. An update and systematic review on drug therapies for the treatment of refractory chronic cough. Expert Opin. Pharmacother. 19, 687\u2013711. https:\/\/doi.org\/10.1080\/14656566.2018.1462795 (2018).","journal-title":"Expert Opin. Pharmacother."},{"key":"99177_CR14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.4168\/aair.2017.9.5.394","volume":"9","author":"W-J Song","year":"2017","unstructured":"Song, W.-J. & Morice, A. H. Cough hypersensitivity syndrome: A few more steps forward. Allergy Asthma Immunol. Res. 9, 394\u2013402 (2017).","journal-title":"Allergy Asthma Immunol. Res."},{"key":"99177_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00540-018-2579-4","volume":"33","author":"M Matsuda","year":"2019","unstructured":"Matsuda, M., Huh, Y. & Ji, R. R. Roles of inflammation, neurogenic inflammation, and neuroinflammation in pain. J. Anesth. 33, 131\u2013139. https:\/\/doi.org\/10.1007\/s00540-018-2579-4 (2019).","journal-title":"J. Anesth."},{"key":"99177_CR16","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s003450100201","volume":"19","author":"U Wesselmann","year":"2001","unstructured":"Wesselmann, U. Neurogenic inflammation and chronic pelvic pain. World J. Urol. 19, 180\u2013185. https:\/\/doi.org\/10.1007\/s003450100201 (2001).","journal-title":"World J. Urol."},{"key":"99177_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0304-3959(97)00112-7","volume":"73","author":"U Wesselmann","year":"1997","unstructured":"Wesselmann, U. & Lai, J. Mechanisms of referred visceral pain: Uterine inflammation in the adult virgin rat results in neurogenic plasma extravasation in the skin. Pain 73, 309\u2013317 (1997).","journal-title":"Pain"},{"key":"99177_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nrn3617","volume":"15","author":"DN Xanthos","year":"2014","unstructured":"Xanthos, D. N. & Sandkuhler, J. Neurogenic neuroinflammation: Inflammatory CNS reactions in response to neuronal activity. Nat. Rev. Neurosci. 15, 43\u201353. https:\/\/doi.org\/10.1038\/nrn3617 (2014).","journal-title":"Nat. Rev. Neurosci."},{"key":"99177_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.tips.2015.03.004","volume":"36","author":"A Laux-Biehlmann","year":"2015","unstructured":"Laux-Biehlmann, A., d\u2019Hooghe, T. & Zollner, T. M. Menstruation pulls the trigger for inflammation and pain in endometriosis. Trends Pharmacol. Sci. 36, 270\u2013276. https:\/\/doi.org\/10.1016\/j.tips.2015.03.004 (2015).","journal-title":"Trends Pharmacol. Sci."},{"key":"99177_CR20","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.2147\/JPR.S197667","volume":"12","author":"P Zheng","year":"2019","unstructured":"Zheng, P., Zhang, W., Leng, J. & Lang, J. Research on central sensitization of endometriosis-associated pain: A systematic review of the literature. J. Pain Res. 12, 1447\u20131456. https:\/\/doi.org\/10.2147\/JPR.S197667 (2019).","journal-title":"J. Pain Res."},{"key":"99177_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.fertnstert.2011.11.011","volume":"97","author":"B McKinnon","year":"2012","unstructured":"McKinnon, B., Bersinger, N. A., Wotzkow, C. & Mueller, M. D. Endometriosis-associated nerve fibers, peritoneal fluid cytokine concentrations, and pain in endometriotic lesions from different locations. Fertil. Steril. 97, 373\u2013380. https:\/\/doi.org\/10.1016\/j.fertnstert.2011.11.011 (2012).","journal-title":"Fertil. Steril."},{"key":"99177_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tem.2014.10.003","volume":"26","author":"BD McKinnon","year":"2015","unstructured":"McKinnon, B. D., Bertschi, D., Bersinger, N. A. & Mueller, M. D. Inflammation and nerve fiber interaction in endometriotic pain. Trends Endocrinol. Metab. 26, 1\u201310. https:\/\/doi.org\/10.1016\/j.tem.2014.10.003 (2015).","journal-title":"Trends Endocrinol. Metab."},{"key":"99177_CR23","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jmig.2009.07.012","volume":"16","author":"G Wang","year":"2009","unstructured":"Wang, G. et al. Hyperinnervation in intestinal deep infiltrating endometriosis. J. Minim. Invasive Gynecol. 16, 713\u2013719. https:\/\/doi.org\/10.1016\/j.jmig.2009.07.012 (2009).","journal-title":"J. Minim. Invasive Gynecol."},{"key":"99177_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/humrep\/dew293","volume":"32","author":"NP Johnson","year":"2017","unstructured":"Johnson, N. P. et al. World Endometriosis Society consensus on the classification of endometriosis. Hum. Reprod. 32, 315\u2013324. https:\/\/doi.org\/10.1093\/humrep\/dew293 (2017).","journal-title":"Hum. Reprod."},{"key":"99177_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.bpobgyn.2004.01.007","volume":"18","author":"P Vigan\u00f2","year":"2004","unstructured":"Vigan\u00f2, P., Parazzini, F., Somigliana, E. & Vercellini, P. Endometriosis: Epidemiology and aetiological factors. Best Pract. Res. Clin. Obstet. Gynaecol. 18, 177\u2013200. https:\/\/doi.org\/10.1016\/j.bpobgyn.2004.01.007 (2004).","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"99177_CR26","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1093\/humrep\/det284","volume":"28","author":"AA De Graaff","year":"2013","unstructured":"De Graaff, A. A. et al. The significant effect of endometriosis on physical, mental and social wellbeing: Results from an international cross-sectional survey. Hum. Reprod. 28, 2677\u20132685. https:\/\/doi.org\/10.1093\/humrep\/det284 (2013).","journal-title":"Hum. Reprod."},{"key":"99177_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/humupd\/dmt027","volume":"19","author":"L Culley","year":"2013","unstructured":"Culley, L. et al. The social and psychological impact of endometriosis on women\u2019s lives: A critical narrative review. Hum. Reprod. Update 19, 625\u2013639. https:\/\/doi.org\/10.1093\/humupd\/dmt027 (2013).","journal-title":"Hum. Reprod. Update"},{"key":"99177_CR28","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1111\/j.1471-0528.2008.01878.x","volume":"115","author":"KD Ballard","year":"2008","unstructured":"Ballard, K. D., Seaman, H. E., de Vries, C. S. & Wright, J. T. Can symptomatology help in the diagnosis of endometriosis? Findings from a national case-control study\u2014Part 1. BJOG 115, 1382\u20131391. https:\/\/doi.org\/10.1111\/j.1471-0528.2008.01878.x (2008).","journal-title":"BJOG"},{"key":"99177_CR29","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.fertnstert.2007.03.069","volume":"89","author":"N Sinaii","year":"2008","unstructured":"Sinaii, N. et al. Differences in characteristics among 1,000 women with endometriosis based on extent of disease. Fertil. Steril. 89, 538\u2013545. https:\/\/doi.org\/10.1016\/j.fertnstert.2007.03.069 (2008).","journal-title":"Fertil. Steril."},{"key":"99177_CR30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/978-3-030-28741-2_17","volume-title":"Pick Up and Oocyte Management","author":"A Tinelli","year":"2020","unstructured":"Tinelli, A. et al. Pick Up and Oocyte Management 265\u2013289 (Springer, 2020)."},{"key":"99177_CR31","doi-asserted-by":"publisher","unstructured":"Brown, J., Crawford, T. J., Datta, S. & Prentice, A. Oral contraceptives for pain associated with endometriosis. Cochrane Database Syst. Rev. Issue 5. Art. No.: CD001019. https:\/\/doi.org\/10.1002\/14651858 (2018).","DOI":"10.1002\/14651858"},{"key":"99177_CR32","doi-asserted-by":"publisher","unstructured":"Brown, J., Kives, S. & Akhtar, M. Progestagens and anti\u2010progestagens for pain associated with endometriosis. Cochrane Database Syst. Rev. Issue 3. Art. No.: CD002122. https:\/\/doi.org\/10.1002\/14651858 (2012).","DOI":"10.1002\/14651858"},{"key":"99177_CR33","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/humrep\/det457","volume":"29","author":"GA Dunselman","year":"2014","unstructured":"Dunselman, G. A. et al. ESHRE guideline: Management of women with endometriosis. Hum. Reprod. 29, 400\u2013412. https:\/\/doi.org\/10.1093\/humrep\/det457 (2014).","journal-title":"Hum. Reprod."},{"key":"99177_CR34","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40265-018-0928-0","volume":"78","author":"S Ferrero","year":"2018","unstructured":"Ferrero, S., Barra, F. & Maggiore, U. L. R. Current and emerging therapeutics for the management of endometriosis. Drugs 78, 995\u20131012 (2018).","journal-title":"Drugs"},{"key":"99177_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogc.2019.08.004","author":"SS Singh","year":"2019","unstructured":"Singh, S. S., Gude, K., Perdeaux, E., Gattrell, W. T. & Becker, C. M. Surgical outcomes in patients with endometriosis: A systematic review. J. Obstet. Gynaecol. Can. https:\/\/doi.org\/10.1016\/j.jogc.2019.08.004 (2019).","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"99177_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/GCO.0b013e32836343eb","volume":"25","author":"AD DiVasta","year":"2013","unstructured":"DiVasta, A. D. & Laufer, M. R. The use of gonadotropin releasing hormone analogues in adolescent and young patients with endometriosis. Curr. Opin. Obstet. Gynecol. 25, 287\u2013292. https:\/\/doi.org\/10.1097\/GCO.0b013e32836343eb (2013).","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"99177_CR37","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/humrep\/deaa061","volume":"35","author":"S Ding","year":"2020","unstructured":"Ding, S. et al. Activation of ATF3\/AP-1 signaling pathway is required for P2X3-induced endometriosis pain. Hum. Reprod. 35, 1130\u20131144. https:\/\/doi.org\/10.1093\/humrep\/deaa061 (2020).","journal-title":"Hum. Reprod."},{"key":"99177_CR38","doi-asserted-by":"publisher","first-page":"e0184647","DOI":"10.1371\/journal.pone.0184647","volume":"12","author":"S Ding","year":"2017","unstructured":"Ding, S. et al. P2X3 receptor involvement in endometriosis pain via ERK signaling pathway. PLoS ONE 12, e0184647. https:\/\/doi.org\/10.1371\/journal.pone.0184647 (2017).","journal-title":"PLoS ONE"},{"key":"99177_CR39","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1523\/jneurosci.3229-12.2013","volume":"33","author":"EK Joseph","year":"2013","unstructured":"Joseph, E. K., Green, P. G., Bogen, O., Alvarez, P. & Levine, J. D. Vascular endothelial cells mediate mechanical stimulation-induced enhancement of endothelin hyperalgesia via activation of P2X2\/3 receptors on nociceptors. J. Neurosci. 33, 2849\u20132859. https:\/\/doi.org\/10.1523\/jneurosci.3229-12.2013 (2013).","journal-title":"J. Neurosci."},{"key":"99177_CR40","doi-asserted-by":"publisher","first-page":"E1738","DOI":"10.1210\/jc.2014-2282","volume":"99","author":"E Greaves","year":"2014","unstructured":"Greaves, E., Grieve, K., Horne, A. W. & Saunders, P. T. Elevated peritoneal expression and estrogen regulation of nociceptive ion channels in endometriosis. J. Clin. Endocrinol. Metab. 99, E1738-1743. https:\/\/doi.org\/10.1210\/jc.2014-2282 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"99177_CR41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejogrb.2016.06.017","volume":"209","author":"D Yan","year":"2017","unstructured":"Yan, D., Liu, X. & Guo, S. W. Nerve fibers and endometriotic lesions: Partners in crime in inflicting pains in women with endometriosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 209, 14\u201324. https:\/\/doi.org\/10.1016\/j.ejogrb.2016.06.017 (2017).","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"99177_CR42","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0304-3940(01)01906-1","volume":"306","author":"KJ Berkley","year":"2001","unstructured":"Berkley, K. J., Cason, A., Jacobs, H., Bradshaw, H. & Wood, E. Vaginal hyperalgesia in a rat model of endometriosis. Neurosci. Lett. 306, 185\u2013188 (2001).","journal-title":"Neurosci. Lett."},{"key":"99177_CR43","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1056\/NEJMoa1700089","volume":"377","author":"HS Taylor","year":"2017","unstructured":"Taylor, H. S. et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N. Engl. J. Med. 377, 28\u201340 (2017).","journal-title":"N. Engl. J. Med."},{"key":"99177_CR44","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1016\/j.bmcl.2016.07.013","volume":"26","author":"G Sz\u00e1nt\u00f3","year":"2016","unstructured":"Sz\u00e1nt\u00f3, G. et al. New P2X3 receptor antagonists. Part 2: Identification and SAR of quinazolinones. Bioorganic Med. Chem. Lett. 26, 3905\u20133912. https:\/\/doi.org\/10.1016\/j.bmcl.2016.07.013 (2016).","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"99177_CR45","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.bmcl.2019.01.039","volume":"29","author":"H Tobinaga","year":"2019","unstructured":"Tobinaga, H. et al. Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 2: Discovery of orally bioavailable compounds. Bioorganic Med. Chem. Lett. 29, 688\u2013693. https:\/\/doi.org\/10.1016\/j.bmcl.2019.01.039 (2019).","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"99177_CR46","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.bmcl.2017.04.060","volume":"28","author":"H Tobinaga","year":"2018","unstructured":"Tobinaga, H. et al. Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 1: Initial structure-activity relationship studies of a hit from a high throughput screening. Bioorganic Med. Chem. Lett. 28, 2338\u20132342. https:\/\/doi.org\/10.1016\/j.bmcl.2017.04.060 (2018).","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"99177_CR47","unstructured":"Smith, J. A., Kitt, M. M., Sher, M. R., Butera, P. & Ford, A. P. In D23. Symptoms matter: Cough, Dyspnea, Fatigue and Quality of Life A6524-A6524 (2016)."},{"key":"99177_CR48","unstructured":"Strand, V. et al. Abstract - an exploratory 4-week study of a P2X3 antagonist AF-219 in the treatment of patients with osteoarthritis (OA) of the knee. In Presented at the 2014 ACR\/ARHP Annual Meeting, Boston, MA, USA, A2240 (14\u201319 November 2014)."},{"key":"99177_CR49","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.bbi.2011.08.004","volume":"26","author":"J Arnold","year":"2012","unstructured":"Arnold, J. et al. Imbalance between sympathetic and sensory innervation in peritoneal endometriosis. Brain Behav Immun 26, 132\u2013141. https:\/\/doi.org\/10.1016\/j.bbi.2011.08.004 (2012).","journal-title":"Brain Behav Immun"},{"key":"99177_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2013.00264","author":"SC Kinnamon","year":"2013","unstructured":"Kinnamon, S. C. & Finger, T. E. A taste for ATP: Neurotransmission in taste buds. Front. Cell Neurosci. https:\/\/doi.org\/10.3389\/fncel.2013.00264 (2013).","journal-title":"Front. Cell Neurosci."},{"key":"99177_CR51","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1111\/bph.14677","volume":"176","author":"D Richards","year":"2019","unstructured":"Richards, D., Gever, J. R., Ford, A. P. & Fountain, S. J. Action of MK-7264 (gefapixant) at human P2X3 and P2X2\/3 receptors and in vivo efficacy in models of sensitisation. Br. J. Pharmacol. 176, 2279\u20132291. https:\/\/doi.org\/10.1111\/bph.14677 (2019).","journal-title":"Br. J. Pharmacol."},{"key":"99177_CR52","doi-asserted-by":"crossref","unstructured":"Morice, A. H. et al. In D93. Evaluation and Novel Treatment Approach for Chronic Cough American Thoracic Society International Conference Abstracts A7648-A7648 (American Thoracic Society, 2020).","DOI":"10.1164\/ajrccm-conference.2020.201.1_MeetingAbstracts.A7648"},{"key":"99177_CR53","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3389\/fphar.2017.00661","volume":"8","author":"G Burnstock","year":"2017","unstructured":"Burnstock, G. Purinergic signalling: Therapeutic developments. Front. Pharmacol. 8, 661 (2017).","journal-title":"Front. Pharmacol."},{"key":"99177_CR54","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00109-014-1135-4","volume":"92","author":"ML Barcena de Arellano","year":"2014","unstructured":"Barcena de Arellano, M. L. & Mechsner, S. The peritoneum\u2014An important factor for pathogenesis and pain generation in endometriosis. J. Mol. Med. 92, 595\u2013602. https:\/\/doi.org\/10.1007\/s00109-014-1135-4 (2014).","journal-title":"J. Mol. Med."},{"key":"99177_CR55","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11302-011-9271-6","volume":"8","author":"AP Ford","year":"2012","unstructured":"Ford, A. P. In pursuit of P2X3 antagonists: Novel therapeutics for chronic pain and afferent sensitization. Purinergic Signal 8, 3\u201326. https:\/\/doi.org\/10.1007\/s11302-011-9271-6 (2012).","journal-title":"Purinergic Signal"},{"key":"99177_CR56","doi-asserted-by":"publisher","first-page":"8171","DOI":"10.2147\/IJN.S146569","volume":"12","author":"M Yuan","year":"2017","unstructured":"Yuan, M. et al. Effect of A-317491 delivered by glycolipid-like polymer micelles on endometriosis pain. Int. J. Nanomedicine 12, 8171\u20138183. https:\/\/doi.org\/10.2147\/IJN.S146569 (2017).","journal-title":"Int. J. Nanomedicine"},{"key":"99177_CR57","doi-asserted-by":"crossref","unstructured":"Lorcan McGarvey, A. H. M. et al. Efficacy and safety of eliapixant in refractory chronic cough: Results of the PAGANINI 12-week, randomized, placebo-controlled Phase 2b study. ERS Virtual International Congress 2021 (2021).","DOI":"10.1183\/13993003.congress-2021.PA562"},{"key":"99177_CR58","doi-asserted-by":"publisher","first-page":"1900439","DOI":"10.1183\/13993003.00439-2019","volume":"54","author":"AH Morice","year":"2019","unstructured":"Morice, A. H. et al. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: A randomised placebo-controlled study. Eur. Respir. J. 54, 1900439. https:\/\/doi.org\/10.1183\/13993003.00439-2019 (2019).","journal-title":"Eur. Respir. J."},{"key":"99177_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(19)30471-0","author":"JA Smith","year":"2020","unstructured":"Smith, J. A. et al. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: A randomised, double-blind, controlled, parallel-group, phase 2b trial. Lancet Respir. Med. https:\/\/doi.org\/10.1016\/s2213-2600(19)30471-0 (2020).","journal-title":"Lancet Respir. Med."},{"key":"99177_CR60","doi-asserted-by":"publisher","first-page":"1901615","DOI":"10.1183\/13993003.01615-2019","volume":"55","author":"JA Smith","year":"2020","unstructured":"Smith, J. A. et al. Gefapixant in two randomised dose-escalation studies in chronic cough. Eur. Respir. J. 55, 1901615. https:\/\/doi.org\/10.1183\/13993003.01615-2019 (2020).","journal-title":"Eur. Respir. J."},{"key":"99177_CR61","doi-asserted-by":"crossref","unstructured":"McGarvey, L. et al. Late breaking abstract\u2014two phase 3 randomized clinical trials of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough (COUGH-1 and COUGH-2). In Presented at the ERS International Virtual Congress 2020, 7\u20139 Sept (2020).","DOI":"10.1183\/13993003.congress-2020.3800"},{"key":"99177_CR62","doi-asserted-by":"publisher","first-page":"RCT452","DOI":"10.1183\/13993003.congress-2019.RCT452","volume":"54","author":"A Niimi","year":"2019","unstructured":"Niimi, A., Ishihara, H., Hida, H. & Miyazaki, S. Late Breaking Abstract - Phase 2a randomised, double-blind, placebo-controlled, crossover study of a novel P2X3 receptor antagonist S-600918 in patients with refractory chronic cough. Eur. Respir. J. 54, RCT452. https:\/\/doi.org\/10.1183\/13993003.congress-2019.RCT452 (2019).","journal-title":"Eur. Respir. J."},{"key":"99177_CR63","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pupt.2019.03.007","volume":"56","author":"D Garceau","year":"2019","unstructured":"Garceau, D. & Chauret, N. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration. Pulm. Pharmacol. Ther. 56, 56\u201362. https:\/\/doi.org\/10.1016\/j.pupt.2019.03.007 (2019).","journal-title":"Pulm. Pharmacol. Ther."},{"key":"99177_CR64","unstructured":"Bellus Health. BLU-5937: Phase 2 RELIEF Trial in Refractory Chronic Cough, https:\/\/bellushealth.com\/pipeline\/blu-5937\/#chronic-cough (2020)."},{"key":"99177_CR65","doi-asserted-by":"publisher","first-page":"11890","DOI":"10.1523\/JNEUROSCI.0698-12.2012","volume":"32","author":"A Serrano","year":"2012","unstructured":"Serrano, A. et al. Differential expression and pharmacology of native P2X receptors in rat and primate sensory neurons. J. Neurosci. 32, 11890\u201311896. https:\/\/doi.org\/10.1523\/JNEUROSCI.0698-12.2012 (2012).","journal-title":"J. Neurosci."},{"key":"99177_CR66","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1016\/j.bmcl.2012.01.124","volume":"22","author":"LD Cantin","year":"2012","unstructured":"Cantin, L. D. et al. Discovery of P2X3 selective antagonists for the treatment of chronic pain. Bioorg. Med. Chem. Lett. 22, 2565\u20132571. https:\/\/doi.org\/10.1016\/j.bmcl.2012.01.124 (2012).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"99177_CR67","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00408-020-00377-8","volume":"198","author":"PV Dicpinigaitis","year":"2020","unstructured":"Dicpinigaitis, P. V., McGarvey, L. P. & Canning, B. J. P2X3-receptor antagonists as potential antitussives: Summary of current clinical trials in chronic cough. Lung 198, 609\u2013616. https:\/\/doi.org\/10.1007\/s00408-020-00377-8 (2020).","journal-title":"Lung"},{"key":"99177_CR68","unstructured":"Wei, Z. L. et al. Amide compounds, compositions and uses thereof (Patent number: WO 2009110985 A2). (2009)."},{"key":"99177_CR69","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1744-8069-10-26","volume":"10","author":"RP Bonin","year":"2014","unstructured":"Bonin, R. P., Bories, C. & De Koninck, Y. A simplified up-down method (SUDO) for measuring mechanical nociception in rodents using von Frey filaments. Mol. Pain 10, 26. https:\/\/doi.org\/10.1186\/1744-8069-10-26 (2014).","journal-title":"Mol. Pain"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99177-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99177-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99177-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T14:39:11Z","timestamp":1725892751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99177-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,6]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["99177"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-99177-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,6]]},"assertion":[{"value":"24 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.J.D., I.N., F.M., A-M.C., S.B., N.C., M.J.G., and S.D.H. are employees of Evotec. N.B., M.K., A.R., J.N., A.L-B., T.M.Z., and O.M.F. are employees of Bayer. Bayer holds a patent on eliapixant (BAY\u00a01817080). A.J.D., I.N., J.N., N.B., O.M.F., A.R., and A.M.C. are inventors on this patent application.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19877"}}